Melphalan Amarox (Melphalan Hydrochloride)

Melphalan hydrochloride, the active ingredient in Melphalan Amarox, is an alkylating agent presented as a sterile injectable for intraarterial and intravenous use. It treats multiple myeloma, ovarian cancer and malignant melanoma in adult patients.

GNH USA supplies Melphalan Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan Amarox is an alkylating antineoplastic agent used in the treatment of certain solid tumours and hematologic malignancies.

Multiple Myeloma: incorporated into combination regimens to achieve disease control. Ovarian Cancer: employed to target rapidly dividing cancer cells and improve response rates. Malignant Melanoma: applied in selected cases to induce tumour regression.

Melphalan Amarox may cause a range of adverse reactions, some of which are expected with cytotoxic chemotherapy.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during infusion. - Myelosuppression: reduced white blood cells, platelets, and red cells. - Fatigue: generalized tiredness during treatment cycles. - Mucositis: inflammation of the oral mucosa. - Alopecia: temporary hair loss. - Diarrhoea: loose stools may occur.

Serious or Rare Side Effects: - Secondary leukaemia: rare but documented long‑term risk. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis in rare cases. - Renal impairment: acute kidney injury with high doses. - Cardiotoxicity: rare cardiac arrhythmias or dysfunction.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for toxicity.

Renal function: assess baseline creatinine and monitor during treatment. Hematologic status: perform regular complete blood counts. Pregnancy: avoid use unless benefits outweigh potential fetal risk. Concomitant radiation: use with caution as combined toxicity may increase. Drug interactions: review all concomitant medications for potential interactions. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Melphalan Amarox can interact with several drug classes; awareness helps minimise adverse outcomes.

Major Interactions (Avoid): - Live vaccines: contraindicated because of immunosuppression. - Strong CYP450 inducers (e.g., rifampin): may reduce melphalan exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased bleeding risk; monitor INR or PT. - Nephrotoxic agents: may exacerbate renal toxicity; monitor kidney function. - Other alkylating agents: additive myelosuppression; adjust dosing as needed.